FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965751775> ?p ?o ?g. }

• W2965751775 endingPage "5094" @default.
• W2965751775 startingPage "5094" @default.
• W2965751775 abstract "5094 Background: A critical survival step for proliferating endothelial cells is the ligation of fibronectin in the extracellular matrix to integrin a5β1. Voloxicimab, a chimeric monoclonal antibody, blocks fibronectin binding to a5β1, and induces apoptosis of proliferating endothelial cells. Voloxicimab activity is independent of growth factor stimulus, suggesting that a5β1 signalling occurs downstream of growth factor signalling, and is possibly a final common pathway for the development of neovasculature. Methods: This is a multicenter, open label, phase II study in mCCRCC. Patients (pts) received volociximab 10 mg/kg IV every 2 weeks until disease progression. Pts were evaluated for efficacy every 8 weeks using RECIST criteria. Results: A total of 40 pts were enrolled. All pts were evaluable for safety and efficacy. Median time since first diagnosis was 2.5 years. ECOG score was 0–1 in all pts. Prior nephrectomy occurred in 38 (95%) pts. Nineteen (47.5%) pts had ≥ 2 prior therapy. Twenty one (52.5 %) pts had prior anti agiogenic therapy. Other prior treatment included IL-2 in 15 (37.5%), interferon alpha in 7 (17.5 %), IL-2 + interferon in 2 (5%) pts. Most frequent side effects were fatigue in 27 (67.5%) pts, nausea 14 (35%) pts, dyspnoea 8 (20%) pts and arthralgia 7 (17.5%) pts, of which none were grade 3 or 4. Seven (17.5%) pts had SAEs. Stable disease (SD) was observed in 32 (80 %) pts including 1 confirmed PR. Duration of SD ranged from 2–22 months (mo). Fourteen (35%) pts had time to progression (TTP) between 5.8 to 22 mo: Four (10%) pts had TTP ≥ 14 mo (range 14- 22 mo), 8 (20%) pts had TTP ≥ 6 mo (range 6- 12 mo) and 2 (5%) pts had TTP = 5.8 mo. Median TTP was 4 mo. Median overall survival (OS) has not been reached after 22 mo. OS at 6 mo was 79% and 68% at 22 mo. Six (15%) pts died in the study, 5 (12.5%) pts due to progressive disease and 1 with arrhythmia (unrelated to volociximab). Conclusions: Volociximab is well tolerated at 10 mg/kg q2w. Stable disease is noted in 80 % of pts. Based on clinical activity, a randomized controlled trial is being planned. No significant financial relationships to disclose." @default.
• W2965751775 created "2019-08-13" @default.
• W2965751775 creator A5050649350 @default.
• W2965751775 creator A5071587035 @default.
• W2965751775 creator A5082466279 @default.
• W2965751775 creator A5091177812 @default.
• W2965751775 date "2007-06-20" @default.
• W2965751775 modified "2023-09-26" @default.
• W2965751775 title "Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)" @default.
• W2965751775 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.5094" @default.
• W2965751775 hasPublicationYear "2007" @default.
• W2965751775 type Work @default.
• W2965751775 sameAs 2965751775 @default.
• W2965751775 citedByCount "14" @default.
• W2965751775 countsByYear W29657517752012 @default.
• W2965751775 countsByYear W29657517752013 @default.
• W2965751775 countsByYear W29657517752016 @default.
• W2965751775 countsByYear W29657517752019 @default.
• W2965751775 countsByYear W29657517752022 @default.
• W2965751775 countsByYear W29657517752023 @default.
• W2965751775 crossrefType "journal-article" @default.
• W2965751775 hasAuthorship W2965751775A5050649350 @default.
• W2965751775 hasAuthorship W2965751775A5071587035 @default.
• W2965751775 hasAuthorship W2965751775A5082466279 @default.
• W2965751775 hasAuthorship W2965751775A5091177812 @default.
• W2965751775 hasConcept C121332964 @default.
• W2965751775 hasConcept C126322002 @default.
• W2965751775 hasConcept C141071460 @default.
• W2965751775 hasConcept C142424586 @default.
• W2965751775 hasConcept C143998085 @default.
• W2965751775 hasConcept C2777472916 @default.
• W2965751775 hasConcept C2780580376 @default.
• W2965751775 hasConcept C29730261 @default.
• W2965751775 hasConcept C31760486 @default.
• W2965751775 hasConcept C71924100 @default.
• W2965751775 hasConcept C87355193 @default.
• W2965751775 hasConcept C90924648 @default.
• W2965751775 hasConceptScore W2965751775C121332964 @default.
• W2965751775 hasConceptScore W2965751775C126322002 @default.
• W2965751775 hasConceptScore W2965751775C141071460 @default.
• W2965751775 hasConceptScore W2965751775C142424586 @default.
• W2965751775 hasConceptScore W2965751775C143998085 @default.
• W2965751775 hasConceptScore W2965751775C2777472916 @default.
• W2965751775 hasConceptScore W2965751775C2780580376 @default.
• W2965751775 hasConceptScore W2965751775C29730261 @default.
• W2965751775 hasConceptScore W2965751775C31760486 @default.
• W2965751775 hasConceptScore W2965751775C71924100 @default.
• W2965751775 hasConceptScore W2965751775C87355193 @default.
• W2965751775 hasConceptScore W2965751775C90924648 @default.
• W2965751775 hasIssue "18_suppl" @default.
• W2965751775 hasLocation W29657517751 @default.
• W2965751775 hasOpenAccess W2965751775 @default.
• W2965751775 hasPrimaryLocation W29657517751 @default.
• W2965751775 hasRelatedWork W2073021016 @default.
• W2965751775 hasRelatedWork W2104532118 @default.
• W2965751775 hasRelatedWork W2312614833 @default.
• W2965751775 hasRelatedWork W2327884061 @default.
• W2965751775 hasRelatedWork W2408936780 @default.
• W2965751775 hasRelatedWork W2412964568 @default.
• W2965751775 hasRelatedWork W2528057197 @default.
• W2965751775 hasRelatedWork W3080325851 @default.
• W2965751775 hasRelatedWork W4232574931 @default.
• W2965751775 hasRelatedWork W4237242722 @default.
• W2965751775 hasVolume "25" @default.
• W2965751775 isParatext "false" @default.
• W2965751775 isRetracted "false" @default.
• W2965751775 magId "2965751775" @default.
• W2965751775 workType "article" @default.